Jefferies analyst Stephen Barker downgraded PeptiDream to Hold from Buy with a price target of 1,300 yen, down from 1,600 yen. The downgrade reflects eliminating the estimated contribution from a peptide that Bristol Myers Squibb was developing in Phase 1 trials.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PPTDF: